There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

The dramatic growth in advanced therapies has led to greater demand for viral vectors, and the need for higher titers of lentiviral vectors. According to VIVEBiotech, a CDMO that specializes in ...

An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...

Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...